Restricted accessResearch articleFirst published online 2023-11
Expected Basal Insulin Requirement During Continuous Subcutaneous Insulin Infusion Therapy by Age Group,Sex,and Body Mass Index,Based on 25,718 Young People with Type 1 Diabetes in the DPV Registry
Since the introduction of insulin pumps into the therapy of pediatric subjects, different approaches have been taken to find optimal basal rates. Previously, the DPV registry provided circadian basal rate patterns for different age groups. As the number of pump users has increased recently and short-acting insulin analogues are now predominant, we performed a new analysis with a larger data pool.
Methods:
We included all recent basal profiles from type 1 diabetes (T1D) patients between 1 and 25 years from the DPV 2021 data pool. We excluded night-time-only pump users, human regular insulin users, and daily basal rates <0.05 and >1.0 U/(kgBW·d).
Results:
In the analysis of profiles from 25,718 young persons with T1D, differences in the daily pattern of basal rates were found between age groups. In addition, we saw significant (P < 0.001) differences in total daily basal dose between genders in all age groups except adults. In addition, the shape of the expected basal-rate pattern differed by body mass index, HbA1c, and use of continuous glucose monitoring.
Discussion:
This analysis demonstrates multiple factors influencing basal patterns and insulin requirement, including age group, gender, overweight, HbA1c, bolus frequency, and sensor use. As circadian basal rates are still mandatory for initiating insulin pump therapy with or without automation, a multimodal approach is necessary to estimate optimal basal rates.
Get full access to this article
View all access options for this article.
References
1.
SchöttlerH, AuzanneauM, BestF, et al.Insulin pump, continuous and capillary glucose monitoring in children, adolescents and adults with diabetes mellitus: DPV registry data between 1995–2019. Diabetologie und Stoffwechsel;, 2020; doi: 10.1055/a-1259-1190
2.
van den BoomL, AuzanneauM, WoelfleJ, et al.Use of continuous glucose monitoring in pump therapy sensor augmented pump or automated insulin delivery in different age groups (0.5 to <26 years) with type 1 diabetes from 2018 to 2021: Analysis of the German/Austrian/Swiss/Luxemburg DPV Registry. J Diabetes Sci Technol 2023; In Press;, 19322968231156601; doi: 10.1177/19322968231156601
3.
AlvarengaCS, La BancaRO, NerisRR, et al.Use of continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes mellitus: A systematic mapping review. BMC Endocr Disord, 2022; 22(1):43; doi: 10.1186/s12902-022-00950-7
4.
WizemannE, RennerR, HeppK. Prospective evaluation of a standardized basal rate distribution for CSII in type 1 diabetes over 6months. Diabet Stoffw, 2001; 10:57.
5.
ConradSC, McGrathMT, GitelmanSE. Transition from multiple daily injections to continuous subcutaneous insulin infusion in type 1 diabetes mellitus. J Pediatr, 2002; 140(2):235–240; doi: 10.1067/mpd.2002.120509
6.
DanneT, BattelinoT, KordonouriO, et al.A cross-sectional international survey of continuous subcutaneous insulin infusion in 377 children and adolescents with type 1 diabetes mellitus from 10 countries. Pediatr Diabetes, 2005; 6(4):193–198; doi: 10.1111/j.1399-543X.2005.00131.x
7.
NauckMA, Kahle-StephanM, LindmeyerAM, et al.Prediction of individual basal rate profiles from patient characteristics in type 1 diabetes on insulin pump therapy. J Diabetes Sci Technol, 2021; 15(6):1273–1281; doi: 10.1177/1932296820972691
8.
HolterhusPM, OdendahlR, OesingmannS, et al.Classification of distinct baseline insulin infusion patterns in children and adolescents with type 1 diabetes on continuous subcutaneous insulin infusion therapy. Diabetes Care, 2007; 30(3):568–573; doi: 10.2337/dc06-2105
9.
DemirG, Atik AltınokY, ÖzenS, et al.Initial basal and bolus rates and basal rate variability during pump treatment in children and adolescents. J Clin Res Pediatr Endocrinol, 2021; 13(2):198–203; doi: 10.4274/jcrpe.galenos.2020.2020.0171
10.
RilstoneS, ReddyM, OliverN. A pilot study of flat and circadian insulin infusion rates in continuous subcutaneous insulin infusion (CSII) in adults with type 1 diabetes (FIRST1D). J Diabetes Sci Technol, 2021; 15(3):666–671; doi: 10.1177/1932296820906195
11.
LaimerM, MelmerA, MaderJK, et al.Variability of basal rate profiles in insulin pump therapy and association with complications in type 1 diabetes mellitus. PLoS One, 2016; 11(3):e0150604; doi: 10.1371/journal.pone.0150604
12.
NauckMA, LindmeyerAM, MathieuC, et al.Twenty-four hour fasting (basal rate) tests to achieve custom-tailored, hour-by-hour basal insulin infusion rates in patients with type 1 diabetes using insulin pumps (CSII). J Diabetes Sci Technol, 2021; 15(2):360–370; doi: 10.1177/1932296819882752
13.
GrunbergerG, AbelsethJM, BaileyTS, et al.Consensus statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. Endocr Pract, 2014; 20(5):463–489.
14.
PhillipM, BattelinoT, RodriguezH, et al.Use of insulin pump therapy in the pediatric age-group: Consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2007; 30(6):1653–1662; doi: 10.2337/dc07-9922.
15.
KarakusKE, Yesiltepe MutluG, GokceT, et al.Insulin requirements for basal and auto-correction insulin delivery in Advanced Hybrid Closed-Loop System: 4193 Days' real-world data of children in two different age groups. J Diabetes Sci Technol, 2022; In Press; 19322968221106194; doi: 10.1177/19322968221106194
16.
LindmeyerAM, MeierJJ, NauckMA. Patients with type 1 diabetes treated with insulin pumps need widely heterogeneous basal rate profiles ranging from negligible to pronounced diurnal variability. J Diabetes Sci Technol, 2021; 15(6):1262–1272; doi: 10.1177/1932296820949939
17.
PhillipM, NimriR, BergenstalRM, et al.Consensus Recommendations for the use of automated insulin delivery technologies in clinical practice. Endocr Rev, 2023; 44(2):254–280; doi: 10.1210/endrev/bnac022
18.
HermannJM, MillerKM, HoferSE, et al.The Transatlantic HbA1c gap: Differences in glycaemic control across the lifespan between people included in the US T1D Exchange Registry and those included in the German/Austrian DPV registry. Diabet Med, 2020; 37(5):848–855; doi: 10.1111/dme.14148
19.
LanzingerS, ZimmermannA, RanjanAG, et al.A collaborative comparison of International Pediatric Diabetes Registries. Pediatr Diabetes, 2022; 23(6):627–640; doi: 10.1111/pedi.13362
20.
KlinkertC, BachranR, HeidtmannB, et al.Age-specific characteristics of the basal insulin-rate for pediatric patients on CSII. Exp Clin Endocrinol Diabetes, 2008; 116(2):118–122; doi: 10.1055/s-2007-990296
21.
BachranR, BeyerP, KlinkertC, et al.Basal rates and circadian profiles in continuous subcutaneous insulin infusion (CSII) differ for preschool children, prepubertal children, adolescents and young adults. Pediatr Diabetes, 2012; 13(1):1–5; doi: 10.1111/j.1399-5448.2011.00777.x
22.
Kromeyer-HauschildK, MossA, WabitschM. Referenzwerte für den Body-Mass-Index für Kinder, Jugendliche und Erwachsene in Deutschland. Anpassung der AGA-BMI-Referenz im Altersbereich von 15 bis 18 Jahren. Adipositas, 2015; 9(3):123–127; doi: 10.1055/s-0037-1618928
23.
ForlenzaGP, PyleLL, MaahsDM, et al.Ambulatory glucose profile analysis of the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Dataset—Applications to the pediatric diabetes population. Pediatr Diabetes, 2017; 18(7):622–628; doi: 10.1111/pedi.12474
24.
van den BoomL, KargesB, AuzanneauM, et al.Temporal trends and contemporary use of insulin pump therapy and glucose monitoring among children, adolescents, and adults with type 1 diabetes between 1995 and 2017. Diabetes Care, 2019; 42(11):2050–2056; doi: 10.2337/dc19-0345
25.
EckertAJ, BramlageP, DanneT, et al.The use of insulin preparations—An evaluation of the DPV registry. Dtsch Ärztebl Int, 2022; 119(38):249–250; doi: 10.3238/arztebl.m2022.0253
26.
HeinemannL, FlemingGA, PetrieJR, et al.Insulin pump risks and benefits: A clinical appraisal of pump safety standards, adverse event reporting, and research needs: A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetes Care, 2015; 38(4):716–722; doi: 10.2337/dc15-0168
27.
KamrathC, TittelSR, KapellenTM, et al.Early versus delayed insulin pump therapy in children with newly diagnosed type 1 diabetes: Results from the multicentre, prospective diabetes follow-up DPV registry. Lancet Child Adolesc Health, 2021; 5(1):17–25; doi: 10.1016/s2352-4642(20)30339-4
28.
DiMeglioLA, AceriniCL, CodnerE, et al.ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatric Diabetes, 2018; 19(Suppl 27):105–114; doi: 10.1111/pedi.12737
29.
HanasR, AdolfssonP. Bolus calculator settings in well-controlled prepubertal children using insulin pumps are characterized by low insulin to carbohydrate ratios and short duration of insulin action time. J Diabetes Sci Technol, 2017; 11(2):247–252; doi: 10.1177/1932296816661348
30.
HegabAM. Diurnal variation of real-life insulin sensitivity factor among children and adolescents with type 1 diabetes using ultra-long-acting basal insulin analogs. Front Pediatr, 2022; 10:854972; doi: 10.3389/fped.2022.854972
31.
OstrovskiI, LovblomLE, ScarrD, et al.Analysis of prevalence, magnitude and timing of the dawn phenomenon in adults and adolescents with type 1 diabetes: Descriptive analysis of 2 Insulin Pump Trials. Can J Diabetes, 2020; 44(3):229–235; doi: 10.1016/j.jcjd.2019.08.003
32.
NimriR, BattelinoT, LaffelLM, et al.Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. Nat Med, 2020; 26(9):1380–1384; doi: 10.1038/s41591-020-1045-7
33.
RohrerT, StierkorbE, HegerS, et al.Delayed pubertal onset and development in German children and adolescents with type 1 diabetes: Cross-sectional analysis of recent data from the DPV diabetes documentation and quality management system. Eur J Endocrinol, 2007; 157(5):647–653; doi: 10.1530/EJE-07-0150
34.
SherrJL, SchoelwerM, Dos SantosTJ, et al.ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery. Pediatr Diabetes, 2022; 23(8):1406–1431; doi: 10.1111/pedi.13421
35.
BurnsideMJ, LewisDM, CrocketHR, et al.Open-source automated insulin delivery in type 1 diabetes. N Engl J Med, 2022; 387(10):869–881; doi: 10.1056/NEJMoa2203913
36.
SherrJL, HeinemannL, FlemingGA, et al.Automated insulin delivery: Benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetologia, 2023; 66(1):3–22; doi: 10.1007/s00125-022-05744-z
37.
BattelinoT, DanneT, BergenstalRM, et al.Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care, 2019; 42(8):1593–1603; doi: 10.2337/dci19-0028
38.
AnderzénJ, HermannJM, SamuelssonU, et al.International benchmarking in type 1 diabetes: Large difference in childhood HbA1c between eight high-income countries but similar rise during adolescence—A quality registry study. Pediatric Diabetes, 2020; 21(4):621–627; doi: 10.1111/pedi.13014
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
